Scientific Journal of

    References:
 

1. Karimi G, Zadsar M, Pourfathollah AA. Seroprevalence and geographical distribution of human T-lymphotropic virus type 1 among volunteer blood donors in endemic areas of Iran. Virol J 2017; 14(1): 1-9.
2. Pirayeshfard L, Sharifi Z, Amini-Kafiabad S, Haghnazari Sadaghiani N. Phylogenetic analysis of HTLV-1 in Iranian blood donors, HIV-1 positive patients and patients with beta thalassemia. J Med Virol 2018; 90(8): 1398-405.
3. Martinez MP, Al-Saleem J, Green PL. Comparative virology of HTLV-1 and HTLV-2. Retrovirology 2019; 16(1): 1-12.
4. Murphy E. Infection with human T-lymphotropic virus types-1 and-2 (HTLV-1 and-2): Implications for blood transfusion safety. Transfus Clin Biol 2016; 23(1): 13-9.
5. Eusebio-Ponce E, Anguita E, Paulino-Ramirez R, Candel FJ. HTLV-1 infection: an emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases. Rev Esp Quimioter 2019; 32(6): 485-96.
6. Braz M, Oliveira JM, Rêgo JL, Carvalho EMd, Santos SMB, Castellucci LC. Polymorphism in the interleukin-10 gene is associated with overactive bladder phenotype associated with HTLV-1 infection. Rev Soc Bras Med Trop 2019; 52: e20180481.
7. Dyck L, Mills KH. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol 2017; 47(5): 765-79.
8. Zhang J, Zhao T, Xu C, Huang J, Yu H. The association between polymorphisms in the PDCD1 gene and the risk of cancer: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2016; 95(40): e4423.
9. Yasuma-Mitobe K, Matsuoka M. The roles of coinhibitory receptors in pathogenesis of human retroviral infections. Front Immunol 2018; 9: 2755.
10. Yamamoto M, Kobayashi T, Mashima H, Miki D, Kuroda S, Hamaoka M, et al. PD1 gene polymorphism is associated with a poor prognosis in hepatocellular carcinoma following liver resection, cohort study. Int J Surg 2020; 80: 84-90.
11. Ilcus C, Bagacean C, Tempescul A, Popescu C, Parvu A, Cenariu M, et al. Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. Onco Targets Ther 2017; 10: 2349-63.
12. Masaki A, Ishida T, Suzuki S, Ito A, Narita T, Kinoshita S, et al. Human T-cell lymphotropic/leukemia virus type 1 (HTLV-1) Tax-specific T-cell exhaustion in HTLV-1-infected individuals. Cancer Sci 2018; 109(8): 2383-90.
13. Zhou RM, Li Y, Wang N, Huang X, Cao SR, Shan BE. Association of programmed death-1 polymorphisms with the risk and prognosis of esophageal squamous cell carcinoma. Cancer genetics 2016; 209(9): 365-75.
14. Pourfathollah AA, Daneshmandi S, Akhlaghi M. The role of PD-1 gene promoteric allele A in rheumatoid arthritis in Iranian patients. Journal of Arak University of Medical Sciences 2012; 14(6): 82-8. [ Article in Farsi]
15. Seliger B. Basis of PD1/PD-L1 therapies. J Clin Med 2019; 8(12): 2168.
16. Salmaninejad A, Khoramshahi V, Azani A, Soltaninejad E, Aslani S, Zamani MR, et al. PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics 2018; 70(2): 73-86.
17. Iwanaga M. Epidemiology of HTLV-1 Infection and ATL in Japan: An Update. Front Microbiol 2020; 11: 1124.
18. Gao P, Lazare C, Cao C, Meng Y, Wu P, Zhi W, et al. Immune checkpoint inhibitors in the treatment of virus-associated cancers. J Hematol Oncol 2019; 12(1): 1-10.
19. Hua Z, Li D, Xiang G, Xu F, Jie G, Fu Z, et al. PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China. Breast Cancer Res Treat 2011; 129(1): 195-201.
20. Zhang G, Liu Z, Duan S, Han Q, Li Z, Lv Y, et al. Association of polymorphisms of programmed cell death-1 gene with chronic hepatitis B virus infection. Hum Immunol 2010; 71(12): 1209-13.

Lack of the association between single nucleotide polymorphism in programmed cell death 1 gene) PD-1(and susceptibility to human lymphotropic virus infection type 1(HTLV-1) in the Iranian population

 

                         Amiri Hezaveh Y.¹, Sharifi Z.¹, Ranjbar Kermani F.¹, Shahabi M.¹, Kheirandish M.^1
 
 
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
 
 
Abstract
Background and Objectives
Human T-cell lymphotropic virus type 1 (HTLV-1) requires cell-to-cell communication to cause infection. The increase in the number of cells infected with virus in turn increases the likelihood of virus transmission and progression of disease. Host immune system responses and genetics factors can affect the susceptibility to virus. Thus, in this study, for the first time the polymorphism in PD-1 gene promoter, which is involved in the negative regulation of immune responses, was evaluated in the HTLV-1 asymptomatic carriers and the healthy controls in the Iranian population in 2020.
 
Materials and Methods
In this case-control study, genomic DNAs of 81 HTLV-1 asymptomatic carrier  blood donors and 162 healthy blood donors in Khorasan Razavi province were extracted and the rs36084323 polymorphisms  were genotyped with PCR- RFLP method. To confirm the genotyping results, PCR products were sequenced. The results were analyzed using SPSS-22 statistical software based on chi-square test.
 
Results
The frequencies of G and A alleles of rs36084323 polymorphism were 75% and 25% in the control group and 79.6% and 20.4% in the case group, respectively. Considering the G allele as a reference there was no significant difference between the case and control groups (p = 0.256).
 
Conclusions 
The results of this study showed that there is no association between G/A in single nucleotide polymorphism of rs36084323 with susceptibility to HTLV-1 virus infection in the Iranian population.
 
Key words: HTLV-1, Genetic Polymorphism, PCR
 
 
 
 
Received:  11 Nov 2020
Accepted: 27 Feb 2021
 
 

Correspondence: Sharifi Z., PhD of Virology. Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.           
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 82052152; Fax: (+9821) 88601555
E-mail: sharifiz@yahoo.com